Monday, March 21, 2016
Amgen Reports Positive Results In Ostereoposis Study
Thousand Oaks-based Amgen reports that it saw positive top-line results for a study for its romosozumab compound in men with osteoporosis. Amgen said its Phase 3 study demonstrated a significant increase in bone mineral density (BMD) at the lumbar spine, compared with a placebo over 12 months. The study and compound are being develops in a collaboration between Amgen and UCB. Romosozumab is being targeted at both treating women and men with osteoporosis.
Get More SocalTech Data
Try our two week free trial to find new tech customers, find high tech startups and jobs, find venture funding, and more!Learn More